Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer

British Journal of Cancer

Volumn 90, Issue 12, 2004, Pages 2312-2316

  Michalaki, V ^a   Syrigos, K ^b   Charles, P ^a   Waxman, J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cytokines; IL 6; Prostate cancer; TNF

Indexed keywords

CYTOKINE; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; RECURRENT CANCER; STATISTICAL SIGNIFICANCE; TUMOR LOCALIZATION; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE TUMOR; SURVIVAL;

AGED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042823539     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601814     Document Type: Article

References (22)

1. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161: 182-187
2. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322
3. Bok RA, Small EJ (2002) Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2: 918-926
4. Chen T, Wang LH, Farrar WL (2000) Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60: 2132-2135
5. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G (1998) Serum levels of interleukin 6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5: 649-652
6. Deeble PD, Murphy DJ, Parsons SJ, Cox ME (2001) Interleukin-6-and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21: 8471-8482
7. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127-133
8. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z (1998) Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640-4645
9. Huss WJ, Barrios RJ, Foster BA, Greenberg NM (2003) Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 54: 8-16
10. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC (2000) Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42: 239-242
11. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T (2000) Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 164: 800-805
12. Muenchen HJ, Lin DL, Walsh MA, Keller ET, Pienta KJ (2000) Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha 'super-repressor'. Clin Cancer Res 6: 1969-1977
13. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702-2706
14. Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M (1998) Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 4: 1743-1748
15. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71: 354-356
16. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM (2001) Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58: 1008-1015
17. Smith DS, Catalona WJ, Herschman JD (1996) Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 276: 1309-1315
18. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET (2001) Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12: 33-40
19. Spiotto MT, Chung TD (2000) STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42: 88-98
20. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45: 542-549
21. Wise GJ, Marella VK, Talluri G, Shirazian D (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164: 722-725
22. Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, Kishimoto T, Nakatani T (2002) Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 6: 1396-1400